Elrexfio (elranatamab-bcmm)

P2, N=34, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jul 2026 --> Mar 2026

Notably, marked peripheral CD8+ T cell expansion was observed at the onset of response, and counts remained elevated during sustained remission. This case suggests that early sFLC reduction is a useful indicator for treatment continuation, and that peripheral CD8+ T-cell dynamics may serve as an on-treatment response biomarker for elranatamab therapy.

P1, N=59, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=90 --> 59

P2, N=32, Recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Aug 2026

P2, N=30, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting

P2, N=26, Recruiting, Memorial Sloan Kettering Cancer Center

P2, N=46, Active, not recruiting, Pfizer | N=34 --> 46

P1/2, N=24, Recruiting, Celgene Corp.

P2, N=86, Completed, Pfizer | Active, not recruiting --> Completed

P=N/A, N=30, Not yet recruiting, Pfizer

P2, N=34, Not yet recruiting, M.D. Anderson Cancer Center

JTT may enhance the efficacy of T cell-redirecting immunotherapies in RRMM by promoting cytotoxic T cell expansion. These findings warrant further investigation into the use of JTT as an adjunct to improve outcomes in patients with EMD.